Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Alexion to study ULTOMIRIS® therapy re COVID-19

Alexion Pharmaceuticals plans to initiate a global Phase 3 study to investigate ULTOMIRIS® (ravulizumab-cwvz) in a subset of adults with COVID-19 – those who are...

| By Kelley Gipson

BioCT welcomes new members MDG and Hobson

MDG Benefit Solutions is a nationally respected employee benefits brokerage and insurance consulting firm specializing in the implementation of insurance benefit plans and online enrollment...

| By Kelley Gipson

Medtronic provides ventilator progress update

Medtronic reports solid progress in the ramp-up of its ventilator production, as well as collaborating with technology partners and governments to drive new ventilator innovation and...

| By Kelley Gipson

Intensity in clinical trial agreement with BMS

Intensity Therapeutics has entered into a clinical trial collaboration agreement with Bristol Myers Squibb. The program will evaluate the safety and efficacy of Intensity’s lead product...

| By Kelley Gipson

Rallybio startup raises $93 million

A veteran team of Connecticut drug developers has raised $93 million for their startup, Rallybio, which is working to acquire and develop a portfolio of...

| By Kelley Gipson

CT voucher program to focus on critical equipment

In response to the COVID-19 crisis, the Connecticut Manufacturing Innovation Fund Voucher Program will give priority and focus to manufacturers realigning or expanding capacity and...

| By Kelley Gipson

Pfizer to test COVID-19 drug candidate soon

Pfizer has found a leading experimental drug candidate against SARS-CoV-2 and is planning to test the drug in the coming months. Pfizer’s R&D chief Mikael...

| By Kelley Gipson

CSL Behring wages multifront battle against COVID-19

CSL Behring and SAB Biotherapeutics are partnering to combat the coronavirus pandemic with the rapid development of SAB-185, a COVID-19 therapeutic candidate on track for clinical evaluation...